Workflow
喹诺酮类系列原料药及中间体
icon
Search documents
成本压力致业绩背离 司太立回应上交所问询
Core Insights - The company Sitaly (603520.SH) is facing significant challenges, including a 36.45% increase in accounts payable to 509 million yuan, while production and sales of its main product, contrast agents, have declined by 9.21% and 5.65% respectively [3][4] - The company's inventory has increased by 28.05%, raising concerns about the ability to convert high inventory levels into sales amidst declining production and sales [4][5] - There is a notable delay in the completion of construction projects, with a 99.28% increase in construction in progress, while revenue growth is only between 3% and 7% [5][6] Accounts Payable and Production Discrepancy - The increase in accounts payable is attributed to a rise in engineering equipment payments by 79.78 million yuan and procurement payments by 56.20 million yuan, with the latter seeing a significant increase in the fourth quarter of 2024 [4] - The company explained the rise in accounts payable as a strategic decision to secure raw materials at lower prices despite declining production and sales [4][5] Inventory Concerns - As of the end of 2024, the company's inventory balance was 1.105 billion yuan, a decrease of 3.76% year-on-year, but with a notable increase in work-in-progress and finished goods [5] - The company claims that 94.79% of its inventory has a shelf life of less than one year, raising questions about how this inventory will be monetized given the declining production and sales [5] Construction Projects Delays - The company has two major projects that have been over 90% complete for three consecutive years but have not yet been finalized, leading to concerns about the efficiency of capital use [6] - The core project, aimed at producing 1,550 tons of non-ionic CT contrast agent raw materials, has been delayed from December 2024 to December 2025 [6] Financial Performance Decline - In 2024, the company reported revenue of 2.35 billion yuan, a year-on-year increase of 7.02%, but incurred a net loss of 49.09 million yuan, a decline of 211% [8] - The fourth quarter of 2024 saw a particularly sharp decline in performance, with a net loss of 58.07 million yuan, a decrease of 1,281.88% year-on-year, and a drop in gross margin from 24.29% in 2023 to 19.43% in 2024 [8] Factors Contributing to Performance Issues - The decline in profitability is attributed to increased depreciation from new capacity, rising procurement costs due to the strengthening of the US dollar, and sustained high prices for raw materials [8] - Despite a 10% increase in sales revenue, rising sales expenses due to new product launches and market expansion have further squeezed profit margins [8] Shareholder Pledge Situation - As of April 29, 2025, the company's largest shareholder has pledged 46.3 million shares, representing 99.99% of their total holdings, while the second-largest shareholder has pledged 43.6 million shares, representing 96.73% of their total holdings [9]